Latest Conference Articles

Ravi B. Parikh, MD, MPP, discusses how artificial intelligence could shape oncology practice, support personalized treatment decisions, and accelerate clinical research.

Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.

Telisotuzumab adizutecan showed promising survival in pretreated nonsquamous NSCLC, with the most benefit in EGFR wild-type tumors with high c-Met levels.

Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.

Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.

Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.

Kohei Shitara, MD, discusses safety and tolerability findings from G-HOPE-001 evaluating arcotatug tavatecan in previously treated, CLDN18.2-positive advanced gastric cancer.

Kohei Shitara, MD, discusses HERIZON-GEA-01 findings and how to individualize first-line treatment for HER2-positive advanced gastroesophageal adenocarcinoma.

Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.

Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.

Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.

Arvind N. Dasari, MD, MS, reviews a year in neuroendocrine tumors marked by expanding radioligand options, improved classification, and disappointing combination therapies.

Older age, kidney disease, and prior irradiation were linked to elevated myeloid neoplasm risk after lutetium Lu 177 dotatate in a real-world NET analysis.

Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.

Claire K. Mulvey, MD, explains how patient-reported outcomes and QOL assessments reveal NEN symptom burden and help guide treatment.

Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.

Liver transplant led to durable survival in unresectable NET liver metastases; tumor burden predicted outcomes, and recurrence was common but treatable.

Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.

Erica S. Alexander, MD, highlights endovascular approaches to venous occlusion, including stenting and thrombolysis, for select patients with NETs.

Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.

In a phase 1 trial, a single intratumoral injection of oncolytic virus SVV-001 with ipilimumab and nivolumab was safe in high-grade neuroendocrine cancers.

Halfdan Sørbye, MD, PhD, discusses why accurately distinguishing NET G3 from NEC is critical, as the wrong first-line therapy can shorten survival.

Zocilurtatug pelitecan, a DLL3-targeted ADC, showed meaningful responses and managea-ble safety in previously treated epNEC, regardless of DLL3 expression.

In DAREON-7, first-line obrixtamig plus chemo yielded responses across DLL3 expression levels in epNEC, with the most durable in DLL3-high tumors.

In the CABINET trial, cabozantinib extended PFS vs placebo in advanced NETs regardless of hormone functional status, with similar safety across subgroups.

Jennifer R. Eads, MD, discussed radioligand therapy in younger and older patients with NETs, highlighting safety data and gaps in clinical evidence.

PRRT retreatment achieved high disease control in NETs, and longer benefit from first PRRT was tied to longer progression-free survival after retreatment.

Toni Choueiri, MD, discusses KEYNOTE-564 subgroup findings, adjuvant pembrolizumab after nephrectomy, overtreatment risks, and emerging biomarkers in renal cell carcinoma.

The investigational alpha emitter 212Pb-VMT-α-NET yielded encouraging response rates in PRRT-naive SSTR2+ NETs.

Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.